Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| 908 Devices Inc.MASS · Entity 5564 | Director | June 10, 2026 | June 12, 2026 |
| REPLIGEN CORPRGEN · Entity 486 | Director | March 02, 2026 | March 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
908 Devices Inc.
Report date June 10, 2026 · Filed June 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 44,168 |
Reported balance
After 2026-06-10 transaction · row 1
1 source rowRow 1 · 2026-06-10 · Exercise / conversion · Acquired 14,083 · Balance 44,168 F1: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.001, when vested. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-06-10 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-10 · Exercise / conversion · Disposed 14,083 · Balance 0 F1: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.001, when vested. F2: The RSUs became fully vested on June 10, 2026, the day prior to the 2026 Annual Meeting of the Stockholders of 908 Devices Inc. The RSUs have no expiration date. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 13,656 |
Reported balance
After 2026-06-11 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-06-11 · Grant · Acquired 13,656 · Balance 13,656 F1: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.001, when vested. F3: The RSUs become fully vested on June 11, 2027 or the day prior to the 2027 Annual Meeting of the Stockholders of 908 Devices Inc., whichever occurs first, subject to the reporting person's continued service through the applicable vesting date, provided that, if the reporting person terminates their service for any reason, then a prorated number of RSUs will vest. The RSUs have no expiration date. |
| Stock Option (option to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.22 · Expires 2036-06-10 | Direct | 6,209 |
Reported balance
After 2026-06-11 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-06-11 · Grant · Acquired 6,209 · Balance 6,209 F4: The shares underlying the option become vested and exercisable in substantially equal monthly installments over the 12 months following June 11, 2026, subject to the reporting person's continued service through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.001, when vested.
F2: The RSUs became fully vested on June 10, 2026, the day prior to the 2026 Annual Meeting of the Stockholders of 908 Devices Inc. The RSUs have no expiration date.
F3: The RSUs become fully vested on June 11, 2027 or the day prior to the 2027 Annual Meeting of the Stockholders of 908 Devices Inc., whichever occurs first, subject to the reporting person's continued service through the applicable vesting date, provided that, if the reporting person terminates their service for any reason, then a prorated number of RSUs will vest. The RSUs have no expiration date.
F4: The shares underlying the option become vested and exercisable in substantially equal monthly installments over the 12 months following June 11, 2026, subject to the reporting person's continued service through the applicable vesting date.
REPLIGEN CORP
Report date March 02, 2026 · Filed March 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 89,062 |
Reported balance
After 2026-03-02 transaction · row 1
1 source rowRow 1 · 2026-03-02 · Tax withholding · Disposed 9,897 · Balance 89,062 F1: Represents the number of shares withheld by the Issuer to satisfy tax withholding obligations of the reporting person that arose upon the release of restricted stock units. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the number of shares withheld by the Issuer to satisfy tax withholding obligations of the reporting person that arose upon the release of restricted stock units.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
BIOLIFE SOLUTIONS INC
Report date October 06, 2026 · Filed October 09, 2026
Section 16 reporting ended · disclosed 2026-10-09. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2026-10-06 transaction · row 1
1 source rowRow 1 · 2026-10-06 · Disposition to issuer · Disposed 15,046 · Balance 0 F1: Reflects the disposition of shares of common stock ("Common Stock") of BioLife Solutions, Inc. (the "Registrant") in connection with the consummation on October 6, 2026 of the merger of Bravo Merger Sub I, Inc., a Delaware corporation ("Merger Sub 1") with and into the Registrant (the "First Merger"), pursuant to the Agreement and Plan of Merger, dated as of July 21, 2026 (the "Merger Agreement"), by and among the Registrant, Repligen Corporation, a Delaware corporation ("Repligen"), Merger Sub 1 and Bravo Merger Sub II, LLC, a Delaware limited liability company. At the effective time of the First Merger (the "First Merger Effective Time"), each outstanding share of Common Stock was converted into the right to receive $11.25 in cash and 0.1442 shares of Repligen common stock, in each case subject to the terms and conditions of the Merger Agreement. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects the disposition of shares of common stock ("Common Stock") of BioLife Solutions, Inc. (the "Registrant") in connection with the consummation on October 6, 2026 of the merger of Bravo Merger Sub I, Inc., a Delaware corporation ("Merger Sub 1") with and into the Registrant (the "First Merger"), pursuant to the Agreement and Plan of Merger, dated as of July 21, 2026 (the "Merger Agreement"), by and among the Registrant, Repligen Corporation, a Delaware corporation ("Repligen"), Merger Sub 1 and Bravo Merger Sub II, LLC, a Delaware limited liability company. At the effective time of the First Merger (the "First Merger Effective Time"), each outstanding share of Common Stock was converted into the right to receive $11.25 in cash and 0.1442 shares of Repligen common stock, in each case subject to the terms and conditions of the Merger Agreement.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 17, 2025 Filed Mar 19, 2025 20:21 UTC | REPLIGEN CORP RGEN · Entity 486 | Exercise / conversionCommon Stock | 21,756 | $59.52 | $1,294,917.12 |
DisclosureSEC source: 0000950170-25-042026 · ownership.xml · nonDerivative · entry 2 Hunt Anthony · CIK 0001606030 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 163,057 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 17, 2025 Filed Mar 19, 2025 20:21 UTC | REPLIGEN CORP RGEN · Entity 486 | Exercise / conversionCommon Stock | 5,000 | $33.87 | $169,350.00 |
DisclosureSEC source: 0000950170-25-042026 · ownership.xml · nonDerivative · entry 1 Hunt Anthony · CIK 0001606030 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 141,301 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 03, 2025 Filed Mar 4, 2025 18:30 UTC | REPLIGEN CORP RGEN · Entity 486 | Tax withholdingCommon Stock | 10,142 | $155.38 | $1,575,863.96 |
DisclosureSEC source: 0000950170-25-031572 · ownership.xml · nonDerivative · entry 1 Hunt Anthony · CIK 0001606030 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 136,301 F1 · shares: Represents the number of shares withheld by the Issuer to satisfy tax withholding obligations of the reporting person that arose upon the release of restricted stock units. Read SEC document |
| March 02, 2025 Filed Mar 4, 2025 23:49 UTC | 908 Devices Inc. MASS · Entity 5564 | Exercise / conversionRestricted Stock Units · Derivative | 2,058 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-25-002060 · primarydocument.xml · derivative · entry 2 Hunt Anthony · CIK 0001606030 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,058 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.001, when vested. F2 · derivative.exercise_date: The RSUs become vested in substantially equal annual installments over the 3 years following March 2, 2022, subject to the reporting person's continued service through the applicable vesting date, provided that, if the reporting person terminates their service for any reason, then a prorated number of RSUs will vest. The RSUs have no expiration date. F2 · derivative.expiration_date: The RSUs become vested in substantially equal annual installments over the 3 years following March 2, 2022, subject to the reporting person's continued service through the applicable vesting date, provided that, if the reporting person terminates their service for any reason, then a prorated number of RSUs will vest. The RSUs have no expiration date. Read SEC document |
| March 02, 2025 Filed Mar 4, 2025 23:49 UTC | 908 Devices Inc. MASS · Entity 5564 | Exercise / conversionCommon Stock | 2,058 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001562180-25-002060 · primarydocument.xml · nonDerivative · entry 1 Hunt Anthony · CIK 0001606030 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,721 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.001, when vested. Read SEC document |
| February 27, 2025 Filed Feb 28, 2025 21:26 UTC | REPLIGEN CORP RGEN · Entity 486 | Tax withholdingCommon Stock | 2,825 | $156.54 | $442,225.50 |
DisclosureSEC source: 0000950170-25-030051 · ownership.xml · nonDerivative · entry 1 Hunt Anthony · CIK 0001606030 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 146,443 F1 · shares: Represents the number of shares withheld by the Issuer to satisfy tax withholding obligations of the reporting person that arose upon the release of performance stock units. Read SEC document |
| February 24, 2025 Filed Feb 25, 2025 15:18 UTC | REPLIGEN CORP RGEN · Entity 486 | Tax withholdingCommon Stock | 2,380 | $164.74 | $392,081.20 |
DisclosureSEC source: 0000950170-25-026171 · ownership.xml · nonDerivative · entry 1 Hunt Anthony · CIK 0001606030 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 149,268 F1 · shares: Represents the number of shares withheld by the Issuer to satisfy tax withholding obligations of the reporting person that arose upon the release of performance stock units. Read SEC document |
| December 05, 2024 Filed Dec 6, 2024 01:26 UTC | REPLIGEN CORP RGEN · Entity 486 | Exercise / conversionStock Option (Right to Buy) · Derivative | 11,808 | $0.00 Strike: $33.87 | $0.00 |
DisclosureSEC source: 0000950170-24-133812 · ownership.xml · derivative · entry 2 Hunt Anthony · CIK 0001606030 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,856 Underlying: Common Stock · 11,808 shares Expires 2028-02-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: 11,808 of the shares underlying this option have vested. The remaining shares vest as follows: 2,952 shares on March 1, 2025, 2,952 shares on March 1, 2026, and 2,952 shares on March 1, 2027. Read SEC document |
| December 05, 2024 Filed Dec 6, 2024 01:26 UTC | REPLIGEN CORP RGEN · Entity 486 | Exercise / conversionCommon Stock | 11,808 | $33.87 | $399,936.96 |
DisclosureSEC source: 0000950170-24-133812 · ownership.xml · nonDerivative · entry 1 Hunt Anthony · CIK 0001606030 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 151,648 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 21, 2024 Filed Nov 22, 2024 21:52 UTC | REPLIGEN CORP RGEN · Entity 486 | Exercise / conversionStock Option (Right to Buy) · Derivative | 24,246 | $0.00 Strike: $33.87 | $0.00 |
DisclosureSEC source: 0000950170-24-130266 · ownership.xml · derivative · entry 3 Hunt Anthony · CIK 0001606030 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 24,246 shares Expires 2028-02-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This option is fully vested and exercisable. Read SEC document |
| November 21, 2024 Filed Nov 22, 2024 21:52 UTC | REPLIGEN CORP RGEN · Entity 486 | SaleCommon Stock | 24,246 | $139.67 | $3,386,438.82 |
DisclosureSEC source: 0000950170-24-130266 · ownership.xml · nonDerivative · entry 2 Hunt Anthony · CIK 0001606030 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 139,840 F1 · kind: Transaction undertaken consistent with a previously arranged transaction under the reporting person's Rule 10(b)5-1 trading plan, which expired on November 15, 2024. F2 · price: $139.67 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $139.25 to $140.05, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| November 21, 2024 Filed Nov 22, 2024 21:52 UTC | REPLIGEN CORP RGEN · Entity 486 | Exercise / conversionCommon Stock | 24,246 | $33.87 | $821,212.02 |
DisclosureSEC source: 0000950170-24-130266 · ownership.xml · nonDerivative · entry 1 Hunt Anthony · CIK 0001606030 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 164,086 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 10, 2024 Filed Sep 12, 2024 15:35 UTC | REPLIGEN CORP RGEN · Entity 486 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $33.87 | $0.00 |
DisclosureSEC source: 0000950170-24-105742 · ownership.xml · derivative · entry 6 Hunt Anthony · CIK 0001606030 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 24,246 Underlying: Common Stock · 10,000 shares Expires 2028-02-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: This option is fully vested and exercisable. Read SEC document |
| September 10, 2024 Filed Sep 12, 2024 15:35 UTC | REPLIGEN CORP RGEN · Entity 486 | SaleCommon Stock | 604 | $146.67 | $88,588.68 |
DisclosureSEC source: 0000950170-24-105742 · ownership.xml · nonDerivative · entry 5 Hunt Anthony · CIK 0001606030 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 139,840 F1 · kind: Sale of common stock was effected pursuant to a 10(b)5-1 trading plan adopted on November 9, 2023. F5 · price: $146.67 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $146.49 to $146.76, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| September 10, 2024 Filed Sep 12, 2024 15:35 UTC | REPLIGEN CORP RGEN · Entity 486 | SaleCommon Stock | 10,723 | $145.95 | $1,565,021.85 |
DisclosureSEC source: 0000950170-24-105742 · ownership.xml · nonDerivative · entry 4 Hunt Anthony · CIK 0001606030 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 140,444 F1 · kind: Sale of common stock was effected pursuant to a 10(b)5-1 trading plan adopted on November 9, 2023. F4 · price: $145.95 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $145.49 to $146.49, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| September 10, 2024 Filed Sep 12, 2024 15:35 UTC | REPLIGEN CORP RGEN · Entity 486 | SaleCommon Stock | 9,369 | $144.88 | $1,357,380.72 |
DisclosureSEC source: 0000950170-24-105742 · ownership.xml · nonDerivative · entry 3 Hunt Anthony · CIK 0001606030 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 151,167 F1 · kind: Sale of common stock was effected pursuant to a 10(b)5-1 trading plan adopted on November 9, 2023. F3 · price: $144.88 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $144.45 to $145.41, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| September 10, 2024 Filed Sep 12, 2024 15:35 UTC | REPLIGEN CORP RGEN · Entity 486 | SaleCommon Stock | 1,495 | $143.77 | $214,936.15 |
DisclosureSEC source: 0000950170-24-105742 · ownership.xml · nonDerivative · entry 2 Hunt Anthony · CIK 0001606030 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 160,536 F1 · kind: Sale of common stock was effected pursuant to a 10(b)5-1 trading plan adopted on November 9, 2023. F2 · price: $143.77 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $143.44 to $144.28, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| September 10, 2024 Filed Sep 12, 2024 15:35 UTC | REPLIGEN CORP RGEN · Entity 486 | Exercise / conversionCommon Stock | 10,000 | $33.87 | $338,700.00 |
DisclosureSEC source: 0000950170-24-105742 · ownership.xml · nonDerivative · entry 1 Hunt Anthony · CIK 0001606030 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 162,031 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 03, 2024 Filed Sep 4, 2024 23:25 UTC | REPLIGEN CORP RGEN · Entity 486 | Disposition to issuerStock Option (Right to Buy) · Derivative | 13,057 | $0.00 Strike: $192.71 | $0.00 |
DisclosureSEC source: 0000950170-24-103577 · ownership.xml · derivative · entry 2 Hunt Anthony · CIK 0001606030 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,528 Underlying: Common Stock · 13,057 shares Expires 2034-02-27 F1 · shares: On June 28, 2024 (the "Effective Date"), the Issuer and Mr. Hunt entered into an amendment (the "2024 Equity Award Amendment") to certain of Mr. Hunt's equity awards, pursuant to which, effective as of September 1, 2024, Mr. Hunt forfeited two thirds of the number of shares of the Issuer's Common Stock underlying the time-based restricted stock unit award, performance-based restricted stock unit awards and stock option granted to Mr. Hunt on February 27, 2024 that remain outstanding as of the Effective Date. F2 · derivative.exercise_date: Pursuant to the 2024 Equity Award Amendment, one third of the remaining stock options will vest and become exercisable on February 27, 2025, February 27, 2026, and February 27, 2027. Read SEC document |
| September 03, 2024 Filed Sep 4, 2024 23:25 UTC | REPLIGEN CORP RGEN · Entity 486 | Disposition to issuerCommon Stock | 13,146 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-103577 · ownership.xml · nonDerivative · entry 1 Hunt Anthony · CIK 0001606030 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 152,031 F1 · shares: On June 28, 2024 (the "Effective Date"), the Issuer and Mr. Hunt entered into an amendment (the "2024 Equity Award Amendment") to certain of Mr. Hunt's equity awards, pursuant to which, effective as of September 1, 2024, Mr. Hunt forfeited two thirds of the number of shares of the Issuer's Common Stock underlying the time-based restricted stock unit award, performance-based restricted stock unit awards and stock option granted to Mr. Hunt on February 27, 2024 that remain outstanding as of the Effective Date. Read SEC document |
| June 14, 2024 Filed Jun 14, 2024 21:41 UTC | REPLIGEN CORP RGEN · Entity 486 | PurchaseCommon Stock | 2,000 | $124.08 | $248,160.00 |
DisclosureSEC source: 0000950170-24-073836 · ownership.xml · nonDerivative · entry 1 Hunt Anthony · CIK 0001606030 · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 165,177 Read SEC document |
| June 13, 2024 Filed Jun 14, 2024 20:21 UTC | 908 Devices Inc. MASS · Entity 5564 | GrantStock Option (option to buy) · Derivative | 15,996 | $0.00 Strike: $5.94 | $0.00 |
DisclosureSEC source: 0001562180-24-005063 · primarydocument.xml · derivative · entry 4 Hunt Anthony · CIK 0001606030 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,996 Underlying: Common Stock · 15,996 shares Expires 2033-06-15 F5 · derivative.exercise_date: The shares underlying the option become vested and exercisable in substantially equal monthly installments over the 12 months following June 13, 2024, subject to the reporting person's continued service through the applicable vesting date. Read SEC document |
| June 13, 2024 Filed Jun 14, 2024 20:21 UTC | 908 Devices Inc. MASS · Entity 5564 | GrantRestricted Stock Unit · Derivative | 11,364 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-24-005063 · primarydocument.xml · derivative · entry 3 Hunt Anthony · CIK 0001606030 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,364 Underlying: Common Stock · 11,364 shares Expires not disclosed F3 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.001, when vested. F4 · derivative.exercise_date: The RSUs become fully vested on June 13, 2025 or the day prior to the 2025 Annual Meeting of the Stockholders of 908 Devices Inc., whichever occurs first, subject to the reporting person's continued service through the applicable vesting date, provided that, if the reporting person terminates their service for any reason, then a prorated number of RSUs will vest. The RSUs have no expiration date. F4 · derivative.expiration_date: The RSUs become fully vested on June 13, 2025 or the day prior to the 2025 Annual Meeting of the Stockholders of 908 Devices Inc., whichever occurs first, subject to the reporting person's continued service through the applicable vesting date, provided that, if the reporting person terminates their service for any reason, then a prorated number of RSUs will vest. The RSUs have no expiration date. Read SEC document |
| June 12, 2024 Filed Jun 14, 2024 20:21 UTC | 908 Devices Inc. MASS · Entity 5564 | Exercise / conversionRestricted Stock Unit · Derivative | 7,777 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-24-005063 · primarydocument.xml · derivative · entry 2 Hunt Anthony · CIK 0001606030 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,777 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.001, when vested. This transaction represents the settlement of RSUs in shares of Common Stock on their scheduled vesting date. F2 · derivative.exercise_date: The RSUs became fully vested on June 12, 2024, the day prior to the 2024 Annual Meeting of the Stockholders of 908 Devices Inc. The RSUs have no expiration date. F2 · derivative.expiration_date: The RSUs became fully vested on June 12, 2024, the day prior to the 2024 Annual Meeting of the Stockholders of 908 Devices Inc. The RSUs have no expiration date. Read SEC document |
| June 12, 2024 Filed Jun 14, 2024 20:21 UTC | 908 Devices Inc. MASS · Entity 5564 | Exercise / conversionCommon Stock | 7,777 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001562180-24-005063 · primarydocument.xml · nonDerivative · entry 1 Hunt Anthony · CIK 0001606030 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,663 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.001, when vested. This transaction represents the settlement of RSUs in shares of Common Stock on their scheduled vesting date. Read SEC document |
| May 21, 2024 Filed May 22, 2024 21:14 UTC | REPLIGEN CORP RGEN · Entity 486 | SaleCommon Stock | 969 | $171.03 | $165,728.07 |
DisclosureSEC source: 0000950170-24-063594 · ownership.xml · nonDerivative · entry 6 Hunt Anthony · CIK 0001606030 · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 163,177 F1 · kind: Sale of common stock was effected pursuant to a 10(b)5-1 trading plan adopted on November 9, 2023. F7 · price: $171.03 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $170.87 to $171.23, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| May 21, 2024 Filed May 22, 2024 21:14 UTC | REPLIGEN CORP RGEN · Entity 486 | SaleCommon Stock | 3,925 | $170.04 | $667,407.00 |
DisclosureSEC source: 0000950170-24-063594 · ownership.xml · nonDerivative · entry 5 Hunt Anthony · CIK 0001606030 · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 164,146 F1 · kind: Sale of common stock was effected pursuant to a 10(b)5-1 trading plan adopted on November 9, 2023. F6 · price: $170.04 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $169.81 to $170.76, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| May 21, 2024 Filed May 22, 2024 21:14 UTC | REPLIGEN CORP RGEN · Entity 486 | SaleCommon Stock | 2,963 | $169.27 | $501,547.01 |
DisclosureSEC source: 0000950170-24-063594 · ownership.xml · nonDerivative · entry 4 Hunt Anthony · CIK 0001606030 · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 168,071 F1 · kind: Sale of common stock was effected pursuant to a 10(b)5-1 trading plan adopted on November 9, 2023. F5 · price: $169.27 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $168.80 to $169.78, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| May 21, 2024 Filed May 22, 2024 21:14 UTC | REPLIGEN CORP RGEN · Entity 486 | SaleCommon Stock | 3,933 | $168.33 | $662,041.89 |
DisclosureSEC source: 0000950170-24-063594 · ownership.xml · nonDerivative · entry 3 Hunt Anthony · CIK 0001606030 · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 171,034 F1 · kind: Sale of common stock was effected pursuant to a 10(b)5-1 trading plan adopted on November 9, 2023. F4 · price: $168.33 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $167.75 to $168.74, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| May 21, 2024 Filed May 22, 2024 21:14 UTC | REPLIGEN CORP RGEN · Entity 486 | SaleCommon Stock | 4,008 | $167.05 | $669,536.40 |
DisclosureSEC source: 0000950170-24-063594 · ownership.xml · nonDerivative · entry 2 Hunt Anthony · CIK 0001606030 · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 174,967 F1 · kind: Sale of common stock was effected pursuant to a 10(b)5-1 trading plan adopted on November 9, 2023. F3 · price: $167.05 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $166.73 to $167.72, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| May 21, 2024 Filed May 22, 2024 21:14 UTC | REPLIGEN CORP RGEN · Entity 486 | SaleCommon Stock | 4,274 | $166.36 | $711,022.64 |
DisclosureSEC source: 0000950170-24-063594 · ownership.xml · nonDerivative · entry 1 Hunt Anthony · CIK 0001606030 · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 178,975 F1 · kind: Sale of common stock was effected pursuant to a 10(b)5-1 trading plan adopted on November 9, 2023. F2 · price: $166.36 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $165.73 to $166.72, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| March 18, 2024 Filed Mar 20, 2024 20:29 UTC | REPLIGEN CORP RGEN · Entity 486 | GiftCommon Stock | 2,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-034204 · ownership.xml · nonDerivative · entry 1 Hunt Anthony · CIK 0001606030 · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 183,249 F1 · kind: The shares were disposed of in connection with a bona fide gift by the Reporting Person to a donor advised fund. Read SEC document |
| March 08, 2024 Filed Mar 11, 2024 23:43 UTC | REPLIGEN CORP RGEN · Entity 486 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1 | $0.00 Strike: $16.55 | $0.00 |
DisclosureSEC source: 0000950170-24-029523 · ownership.xml · derivative · entry 10 Hunt Anthony · CIK 0001606030 · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1 shares Expires 2024-05-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F10 · derivative.exercise_date: This option is fully vested and exercisable. Read SEC document |
| March 08, 2024 Filed Mar 11, 2024 23:43 UTC | REPLIGEN CORP RGEN · Entity 486 | SaleCommon Stock | 156 | $202.55 | $31,597.80 |
DisclosureSEC source: 0000950170-24-029523 · ownership.xml · nonDerivative · entry 9 Hunt Anthony · CIK 0001606030 · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 185,249 F1 · kind: Sale of common stock was effected pursuant to a 10(b)5-1 trading plan adopted on November 9, 2023. F9 · price: $202.55 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $202.41 to $202.82, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| March 08, 2024 Filed Mar 11, 2024 23:43 UTC | REPLIGEN CORP RGEN · Entity 486 | SaleCommon Stock | 806 | $201.75 | $162,610.50 |
DisclosureSEC source: 0000950170-24-029523 · ownership.xml · nonDerivative · entry 8 Hunt Anthony · CIK 0001606030 · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 185,405 F1 · kind: Sale of common stock was effected pursuant to a 10(b)5-1 trading plan adopted on November 9, 2023. F8 · price: $201.75 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $201.21 to $202.17, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| March 08, 2024 Filed Mar 11, 2024 23:43 UTC | REPLIGEN CORP RGEN · Entity 486 | SaleCommon Stock | 1,305 | $200.56 | $261,730.80 |
DisclosureSEC source: 0000950170-24-029523 · ownership.xml · nonDerivative · entry 7 Hunt Anthony · CIK 0001606030 · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 186,211 F1 · kind: Sale of common stock was effected pursuant to a 10(b)5-1 trading plan adopted on November 9, 2023. F7 · price: $200.56 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $200.18 to $200.76, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| March 08, 2024 Filed Mar 11, 2024 23:43 UTC | REPLIGEN CORP RGEN · Entity 486 | SaleCommon Stock | 1,822 | $199.53 | $363,543.66 |
DisclosureSEC source: 0000950170-24-029523 · ownership.xml · nonDerivative · entry 6 Hunt Anthony · CIK 0001606030 · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 187,516 F1 · kind: Sale of common stock was effected pursuant to a 10(b)5-1 trading plan adopted on November 9, 2023. F6 · price: $199.53 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $199.13 to $200.04, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| March 08, 2024 Filed Mar 11, 2024 23:43 UTC | REPLIGEN CORP RGEN · Entity 486 | SaleCommon Stock | 1,347 | $198.55 | $267,446.85 |
DisclosureSEC source: 0000950170-24-029523 · ownership.xml · nonDerivative · entry 5 Hunt Anthony · CIK 0001606030 · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 189,338 F1 · kind: Sale of common stock was effected pursuant to a 10(b)5-1 trading plan adopted on November 9, 2023. F5 · price: $198.55 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $198.05 to $198.94, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| March 08, 2024 Filed Mar 11, 2024 23:43 UTC | REPLIGEN CORP RGEN · Entity 486 | SaleCommon Stock | 1,666 | $197.39 | $328,851.74 |
DisclosureSEC source: 0000950170-24-029523 · ownership.xml · nonDerivative · entry 4 Hunt Anthony · CIK 0001606030 · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 190,685 F1 · kind: Sale of common stock was effected pursuant to a 10(b)5-1 trading plan adopted on November 9, 2023. F4 · price: $197.39 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $196.98 to $197.96, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| March 08, 2024 Filed Mar 11, 2024 23:43 UTC | REPLIGEN CORP RGEN · Entity 486 | SaleCommon Stock | 6,228 | $196.32 | $1,222,680.96 |
DisclosureSEC source: 0000950170-24-029523 · ownership.xml · nonDerivative · entry 3 Hunt Anthony · CIK 0001606030 · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 192,351 F1 · kind: Sale of common stock was effected pursuant to a 10(b)5-1 trading plan adopted on November 9, 2023. F3 · price: $196.32 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $195.95 to $196.93, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| March 08, 2024 Filed Mar 11, 2024 23:43 UTC | REPLIGEN CORP RGEN · Entity 486 | SaleCommon Stock | 3,377 | $195.49 | $660,169.73 |
DisclosureSEC source: 0000950170-24-029523 · ownership.xml · nonDerivative · entry 2 Hunt Anthony · CIK 0001606030 · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 198,579 F1 · kind: Sale of common stock was effected pursuant to a 10(b)5-1 trading plan adopted on November 9, 2023. F2 · price: $195.49 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $194.90 to $195.88, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| March 08, 2024 Filed Mar 11, 2024 23:43 UTC | REPLIGEN CORP RGEN · Entity 486 | Exercise / conversionCommon Stock | 1 | $16.55 | $16.55 |
DisclosureSEC source: 0000950170-24-029523 · ownership.xml · nonDerivative · entry 1 Hunt Anthony · CIK 0001606030 · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 201,956 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 07, 2024 Filed Mar 7, 2024 21:28 UTC | REPLIGEN CORP RGEN · Entity 486 | Tax withholdingCommon Stock | 2,867 | $195.72 | $561,129.24 |
DisclosureSEC source: 0000950170-24-028016 · ownership.xml · nonDerivative · entry 1 Hunt Anthony · CIK 0001606030 · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 201,955 F1 · shares: Represents the number of shares withheld by the Issuer to satisfy tax withholding obligations of the reporting person that arose upon the release of restricted stock units. Read SEC document |
| March 05, 2024 Filed Mar 7, 2024 01:23 UTC | REPLIGEN CORP RGEN · Entity 486 | Tax withholdingCommon Stock | 7,275 | $195.52 | $1,422,408.00 |
DisclosureSEC source: 0000950170-24-027514 · ownership.xml · nonDerivative · entry 2 Hunt Anthony · CIK 0001606030 · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 204,822 F2 · shares: Represents the number of shares withheld by the Issuer to satisfy tax withholding obligations of the reporting person that arose upon the release of restricted stock units. Read SEC document |
| March 04, 2024 Filed Mar 5, 2024 23:05 UTC | 908 Devices Inc. MASS · Entity 5564 | Exercise / conversionRestricted Stock Unit · Derivative | 2,057 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-24-002324 · primarydocument.xml · derivative · entry 2 Hunt Anthony · CIK 0001606030 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,058 Underlying: Common Stock, par value $0.001 · 4,115 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.001, when vested. F2 · derivative.exercise_date: The RSUs become vested in substantially equal annual installments over the 3 years following March 2, 2022, subject to the reporting person's continued service through the applicable vesting date, provided that, if the reporting person terminates their service for any reason, then a prorated number of RSUs will vest. The RSUs have no expiration date. F2 · derivative.expiration_date: The RSUs become vested in substantially equal annual installments over the 3 years following March 2, 2022, subject to the reporting person's continued service through the applicable vesting date, provided that, if the reporting person terminates their service for any reason, then a prorated number of RSUs will vest. The RSUs have no expiration date. Read SEC document |
| March 04, 2024 Filed Mar 5, 2024 23:05 UTC | 908 Devices Inc. MASS · Entity 5564 | Exercise / conversionCommon Stock, par value $0.001 | 2,057 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001562180-24-002324 · primarydocument.xml · nonDerivative · entry 1 Hunt Anthony · CIK 0001606030 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,886 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.001, when vested. Read SEC document |
| March 04, 2024 Filed Mar 7, 2024 01:23 UTC | REPLIGEN CORP RGEN · Entity 486 | Tax withholdingCommon Stock | 1,111 | $193.99 | $215,522.89 |
DisclosureSEC source: 0000950170-24-027514 · ownership.xml · nonDerivative · entry 1 Hunt Anthony · CIK 0001606030 · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 212,097 F1 · shares: Represents the number of shares withheld by the Issuer to satisfy tax withholding obligations of the reporting person that arose upon the release of performance stock units. Read SEC document |
| March 01, 2024 Filed Mar 5, 2024 02:49 UTC | REPLIGEN CORP RGEN · Entity 486 | Tax withholdingCommon Stock | 3,322 | $191.79 | $637,126.38 |
DisclosureSEC source: 0000950170-24-025302 · ownership.xml · nonDerivative · entry 2 Hunt Anthony · CIK 0001606030 · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 213,208 F2 · shares: Represents the number of shares withheld by the Issuer to satisfy tax withholding obligations of the reporting person that arose upon the release of restricted stock units. Read SEC document |
| February 29, 2024 Filed Mar 5, 2024 02:49 UTC | REPLIGEN CORP RGEN · Entity 486 | GrantCommon Stock | 2,504 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-025302 · ownership.xml · nonDerivative · entry 1 Hunt Anthony · CIK 0001606030 · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 216,530 F1 · shares: Represents 2,504 shares issued pursuant to a Performance Stock Unit ("PSU") award granted to the Issuer on February 24, 2021. The Compensation Committee authorized the issuance of the underlying shares based upon the Issuer's achievement of pre-established performance criteria set forth in the PSU award. Read SEC document |
| February 27, 2024 Filed Mar 1, 2024 02:04 UTC | REPLIGEN CORP RGEN · Entity 486 | GrantStock Option (Right to Buy) · Derivative | 19,585 | $0.00 Strike: $192.71 | $0.00 |
DisclosureSEC source: 0000950170-24-023489 · ownership.xml · derivative · entry 2 Hunt Anthony · CIK 0001606030 · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,585 Underlying: Common Stock · 19,585 shares Expires 2034-02-27 F2 · derivative.exercise_date: One third of the stock options will vest and become exercisable annually on February 27, 2025, February 27, 2026 and February 27, 2027. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.